IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 711,200 shares of the company's stock after selling 19,270 shares during the period. Principal Financial Group Inc. owned 0.87% of IDEXX Laboratories worth $294,039,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories during the 3rd quarter valued at $25,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC boosted its position in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after purchasing an additional 60 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in IDEXX Laboratories in the third quarter valued at about $37,000. Finally, Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories in the fourth quarter worth about $31,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

Shares of NASDAQ:IDXX traded up $3.06 during midday trading on Friday, reaching $455.92. 158,402 shares of the company's stock traded hands, compared to its average volume of 688,096. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a market cap of $37.33 billion, a P/E ratio of 42.71, a PEG ratio of 3.39 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a fifty day simple moving average of $431.50 and a two-hundred day simple moving average of $452.42.

Insider Transactions at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock valued at $6,161,276 over the last 90 days. Corporate insiders own 2.11% of the company's stock.

Analysts Set New Price Targets

IDXX has been the subject of several analyst reports. Morgan Stanley decreased their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Leerink Partners initiated coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price objective for the company. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Leerink Partnrs upgraded IDEXX Laboratories to a "strong-buy" rating in a research note on Monday, December 2nd. Finally, StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Wednesday, February 5th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.